Immune checkpoint inhibitors (ICI) are monoclonal antibodies that enhance T-lymphocyte anti-tumor response through inhibiting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic lymphocyte-associated antigen-4.1 Here, CD274 is linked to neoplasm.